Urinary tract infection in patients with diabetes mellitus

Diabetes Mellitus is a metabolic syndrome of multiple origins, caused by the insulin absence in the bloodstream and/or by the inability of insulin to adequately exert its effects, causing hyperglycemia and subsequent complications in the body's organic systems. Urinary tract infection (UTI) is one of the most frequent due to the glucose increase in blood circulation and the impairment of cellular immunity, creating a favorable environment for the bacteria proliferation at the inflammation spots. This review describes the clinical and therapeutic aspects of diabetes mellitus and urinary tract infection, with guidelines on glucose management in these events. A non-systematic review was carried out in the Virtual Health Library, PubMed, Scielo, and Google Academic databases with the descriptors Diabetes mellitus, Urinary Tract Infection, Hyperglycemia, Bacteriuria, and Urinary Incontinence. The most relevant articles were selected. Pertinent clinical and therapeutic issues were discussed, covering the diabetes factors that contribute to the onset of UTI; urinary tract infection complications in patients with diabetes mellitus; asymptomatic bacteriuria, recurrent urinary tract infections, and urinary incontinence in people with diabetes; treatments for diabetes and urinary tract infection; and the relationship between glucose-lowering medications and UTI. Given the greater susceptibility of people with diabetes to acquire UTI, the combined insight into these diseases is crucial, both for better UTI prevention in diabetics and for the treatment of both.

Download Full-text

Urinary tract infection in critically ill patients with diabetes mellitus: Spectrum of uropathogens and antimicrobial susceptibility pattern

Bali Journal of Anesthesiology ◽

10.4103/bjoa.bjoa_97_20 ◽

2020 ◽

Vol 4 (6) ◽

pp. 55

Author(s):

Nand Kishore ◽

Sagar Modi ◽

Sushant Khanduri ◽

Barnali Kakati

Keyword(s):

Diabetes Mellitus ◽

Urinary Tract Infection ◽

Urinary Tract ◽

Tract Infection ◽

Critically Ill ◽

Antimicrobial Susceptibility ◽

Critically Ill Patients ◽

Susceptibility Pattern ◽

Antimicrobial Susceptibility Pattern ◽

Patients With Diabetes

Download Full-text

URINARY TRACT INFECTION

The Professional Medical Journal ◽

10.29309/tpmj/2011.18.03.2368 ◽

2011 ◽

Vol 18 (03) ◽

pp. 466-469

Author(s):

GHULAM HUSSAIN BALOCH ◽

MUKHTIAR HUSSAIN JAFFERY ◽

CHANDRA MADHUDAS ◽

Bikha Ram Devrajani ◽

Syed Zulfiquar Ali Shah

Keyword(s):

Diabetes Mellitus ◽

Urinary Tract Infection ◽

Urinary Tract ◽

Tract Infection ◽

Diabetes Type 2 ◽

Diabetes Type ◽

Patients With Diabetes ◽

The Mean

Objective: To determine the frequency and pattern of urinary tract infection in patients with diabetes mellitus. Design: Descriptive case series study. Period: February 2009 to July 2009. Setting: Department of medicine at Liaquat University Hospital). Patients and methods: All patients ≥18 years of age, of either gender were known diabetes for ≥ 2 years duration. The infection was labeled when >5/hpf leukocyte in urine and growth of organism on urine for C/S. The blood sugar and hemoglobin A1C (HbA1C) was also advised to evaluate the status of their diabetes i.e. control or poorly control. Result: During study period total 150 diabetic patients were evaluated for urinary tract infection, of which 92(61%) had UTI. Out of ninety two 80(87%) had diabetes type 2 and 12(13%) were diabetes type 1. The female gender was predominant. The mean ± SD for age of patients with type 2 and type 1 diabetes mellitus was 53.52±10.74 and 20.77±1.65 whereas the mean random blood sugar level in patients with type 2 and 1 diabetes was 232.85±5.87 and 288.99 ± 7.87. The mean ± SD for duration of diabetes type 2 and 1 was 4.77±2.31 and 2.56±1.42. The isolated microorganism were Staphylococcus aureus, Escherichia coli, Proteus, Pseudomonas aeruginosa, Klebsiella, Enterobacteriaceae and C.albicans. Conclusions: The urinary tract infection is more prevalent in patients with diabetes mellitus.

Download Full-text

GLIMPSE INTO THE HIDDEN ASPECTS OF URINARY TRACT INFECTION IN PATIENTS WITH DIABETES MELLITUS AND PROSTATOMEGALY

Journal of Evidence Based Medicine and Healthcare ◽

10.18410/jebmh/2016/101 ◽

2016 ◽

Vol 3 (13) ◽

pp. 433-438

Author(s):

Dwijen Das ◽

Kallol Bhattacharjee ◽

Agrawal Piyush ◽

Amit Kumar Kalwar ◽

Giridhari Kar ◽

...

Keyword(s):

Diabetes Mellitus ◽

Urinary Tract Infection ◽

Urinary Tract ◽

Tract Infection ◽

Patients With Diabetes

Download Full-text

Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus

Current Drug Safety ◽

10.2174/1574886314666190206164647 ◽

2019 ◽

Vol 14 (2) ◽

pp. 87-93 ◽

Cited By ~ 7

Author(s):

Mahakpreet Singh ◽

Ruchika Sharma ◽

Anoop Kumar

Keyword(s):

Diabetes Mellitus ◽

Urinary Tract Infection ◽

Urinary Tract ◽

Tract Infection ◽

Diabetic Ketoacidosis ◽

Adverse Drug Reactions ◽

Sglt2 Inhibitor ◽

Sglt2 Inhibitors ◽

Drug Reactions ◽

Authorization Holder

Background:Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is available. Thus, we have tried to find out the risk profile of SGLT2 inhibitors. Materials and Methods: A total of 1,042 studies have been published from Nov. 2012-Nov. 2017 regarding SGLT2 inhibitors. After inclusion and exclusion criteria, 27 studies have been selected for the analysis of risk. Results and Discussion:The emerging evidence indicates various adverse drug reactions such as foot and toe amputation, cancer, diabetic ketoacidosis, bone fracture risk and urinary as well as mycotic genital infection. The causality assessment has shown a correlation between SGLT2 inhibitors and diabetic ketoacidosis and urinary tract infection. Conclusion:In conclusion, Marketing Authorization Holder (MAH) and Regulatory Authorities (RA) should monitor various adverse drug reactions such as diabetic ketoacidosis and urinary tract infection with the use of SGLT2 inhibitor.

Download Full-text